Airfinity further expands into APAC with launch of Japan office

Posted on Mar 22, 2024

After successful expansion into North America last year, Airfinity is proud to be opening a new office in Japan to provide a formal base for its activities across the APAC region. Having already established a strong presence in the country, the move has been met with great enthusiasm and a warm welcome from our existing Japanese clients which includes government departments and leading pharmaceutical companies.

Rasmus Bech Hansen, CEO and Founder, says "Japan has one of the most innovative and vibrant life science ecosystems and is the world’s 2nd largest pharmaceutical market. This week we officially opened our Tokyo office and it’s great to spend time with the team and meet with some of our clients and partners here.

At Airfinity we are humbled by the opportunity to take part in the continued data-driven development of the Japanese health system and industry."

To learn more about the new APAC headquarters and our work within the Japanese market, email us at

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022